HIV resides within anatomical ‘sanctuary sites’ where local drug exposure and viral dynamics may differ significantly from the systemic compartment. Widespread implementation of antiretroviral therapy has seen a significant decline in the incidence of mother-to-child transmission (MTCT) of HIV. In addition to suppression of maternal plasma/genital viral loads, antiretroviral agents that cross the placenta and achieve adequate concentrations in the fetal compartment may exert a greater prophylactic effect.
Penetration of antiretrovirals in the fetal compartment is expressed by accumulation ratios derived from the measurement of drug concentrations in paired maternal plasma and umbilical cord samples. The nucleoside analogues and nevirapine accumulate extensively in cord blood and in the surrounding amniotic fluid, whereas the protease inhibitors (PIs) exhibit low-to-moderate placental accumulation. Early data suggest that high placental/neonatal concentrations are achieved with raltegravir, but to a lesser extent with etravirine and maraviroc (rank order of accumulation: raltegravir/nucleoside reverse transcriptase inhibitor [tenofovir > zidovudine/lamivudine/emtricitabine/stavudine/abacavir] > non-nucleoside reverse transcriptase inhibitor [nevirapine > etravirine] > PI > maraviroc/enfuvirtide). More comprehensive in vivo pharmacokinetic data are required to justify the potential use of these agents as safe and effective options during pregnancy.
References
1.
TownsendC.L., Cortina-BorjaM., PeckhamC.S., de RuiterA., LyallH., TookeyP.A.Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000– 2006. AIDS2008; 22: 973–981.
2.
HillM.D., AbramsonF.P.The significance of plasma protein binding on the fetal/maternal distribution of drugs at steady-state. Clin Pharmacokinet1988; 14: 156–170.
3.
WardR.M.Drug therapy of the fetus. J Clin Pharmacol1993; 33: 780–789.
4.
SymeM.R., PaxtonJ.W., KeelanJ.A.Drug transfer and metabolism by the human placenta. Clin Pharmacokinet2004; 43: 487–514.
5.
CooperE.R., CharuratM., MofensonL.Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr2002; 29: 484–494.
6.
IoannidisJ.P., AbramsE.J., AmmannA.Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/ml. J Infect Dis2001; 183: 539–545.
7.
SperlingR.S., ShapiroD.E., CoombsR.W.Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med1996; 335: 1621–1629.
8.
TaylorS., DaviesS.Antiretroviral drug concentrations in the male and female genital tract: implications for the sexual transmission of HIV. Curr Opin HIV AIDS2010; 5: 335–343.
9.
CohenM.S., GayC., KashubaA.D., BlowerS., PaxtonL.Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med2007; 146: 591–601.
10.
PattersonT.A., BiniendaZ.K., NewportG.D.Transplacental pharmacokinetics and fetal distribution of 2′, 3′-didehydro-3′-deoxythymidine (d4T) and its metabolites in late-term rhesus macaques. Teratology2000; 62: 93–99.
11.
TuntlandT., OdinecsA., PereiraC.M., NosbischC., UnadkatJ.D.In vitro models to predict the in vivo mechanism, rate, and extent of placental transfer of dideoxynucleoside drugs against human immunodeficiency virus. Am J Obstet Gynecol1999; 180: 198–206.
12.
SchenkerS., JohnsonR.F., KingT.S., SchenkenR.S., HendersonG.I.Azidothymidine (zidovudine) transport by the human placenta. Am J Med Sci1990; 299: 16–20.
13.
HendersonG.I., PerezA.B., YangY., HambyR.L., SchenkenR.S., SchenkerS.Transfer of dideoxyinosine across the human isolated placenta. Br J Clin Pharmacol1994; 38: 237–242.
14.
BloomS.L., DiasK.M., BawdonR.E., GilstrapL.C.III. The maternal-fetal transfer of lamivudine in the ex vivo human placenta. Am J Obstet Gynecol1997; 176: 291–293.
15.
CaseyB.M., BawdonR.E.Placental transfer of ritonavir with zidovudine in the ex vivo placental perfusion model. Am J Obstet Gynecol1998; 179: 758–761.
16.
WattsD.H., BrownZ.A., TartaglioneT.Pharmacokinetic disposition of zidovudine during pregnancy. J Infect Dis1991; 163: 226–232.
17.
MoodleyJ., MoodleyD., PillayK.Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J Infect Dis1998; 178: 1327–1333.
18.
MoodleyD., MoodleyJ., CoovadiaH.A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis2003; 187: 725–735.
19.
ChappuyH., TreluyerJ.M., JullienV.Maternal-fetal transfer and amniotic fluid accumulation of nucleoside analogue reverse transcriptase inhibitors in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother2004; 48: 4332–4336.
20.
SiuS.S., YeungJ.H., PangM.W., ChiuP.Y., LauT.K.Placental transfer of Zidovudine in first trimester of pregnancy. Obstet Gynecol2005; 106: 824–827.
21.
MoisanA., DesnoyerA., Bourgeois-MoineA.Placental transfer of antiretroviral drugs in HIV-infected women: a retrospective study from 2002 to 2009.11th International Workshop on Clinical Pharamcology of HIV Therapy. 7–9 April 2010, Sorrento, Italy. Abstract 1.
22.
YehR.F., RezkN.L., KashubaA.D.Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women. Antimicrob Agents Chemother2009; 53: 2367–2374.
23.
MandelbrotL., PeytavinG., FirtionG., FarinottiR.Maternal-fetal transfer and amniotic fluid accumulation of lamivudine in human immunodeficiency virus-infected pregnant women. Am J Obstet Gynecol2001; 184: 153–158.
24.
ConnorE.M., SperlingR.S., GelberR.Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med1994; 331: 1173–1180.
25.
GuayL.A., MusokeP., FlemingT.Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet1999; 354: 795–802.
26.
GazzardB.G., AndersonJ., BabikerA.British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med2008; 9: 563–608.
Public Health Service Task Force.Recommendations for use of antiretroviral drugs in pregnant women for maternal health and interventions to reduce perinatal HIV transmission in the United States. (Updated May 2010. Accessed 28 September 2010.) Available from http://aidsinfo.nih.gov/contentfiles/PerinatalGL.pdf.
29.
de RuiterA., MerceyD., AndersonJ.British HIV Association and Children's HIV Association guidelines for the management of HIV infection in pregnant women 2008. HIV Med2008; 9: 452–502.
30.
ClarkT.N., WhiteC.A., BartlettM.G.Determination of didanosine in maternal plasma, amniotic fluid, fetal and placental tissues by high-performance liquid chromatography-tandem mass spectrometry. Biomed Chromatogr2006; 20: 605–611.
31.
WadeN., UnadkatJ., HuangS.Pharmacokinetics and safety of d4T and 3TC in HIV-infected pregnant women and their infants (PACTG 332).10th Conference on Retroviruses and Opportunistic Infections. 10–14 February 2003, Boston, MA, USA. Abstract 886.
32.
BonoraS., Gonzalez de RequenaD., ChiesaE.Transplacental passage of tenofovir and other antiretrovirals at delivery.14th Conference on Retroviruses and Opportunistic Infections. 25–28 February 2010, Los Angeles, CA, USA. Abstract 738a.
33.
BurchettS., BestB., MirochnickM.Tenofovir pharmacokinetics during pregnancy, at delivery and postpartum.14th Conference on Retroviruses and Opportunistic Infections. 25–28 February 2010, Los Angeles, CA, USA. Abstract 738b.
34.
RodmanJ., FlynnP., ShapiroD.Pharmacokinetics and safety of tenofovir disoproxil fumarate in HIV-1-infected pregnant women and their infants.13th Conference on Retroviruses and Opportunistic Infections. 5–8 February 2010, Denver, CO, USA. Abstract 708.
35.
FlynnP., MirochnickM., ShapiroD.Single dose tenofovir disoproxil fumarate (TDF) with and without emtricitabine (FTC) in HIV-1 infected pregnant women and their infants: pharmacokinetics (PK) and safety.16th Conference on Retroviruses and Opportunistic Infections. 8–11 February 2009, Montreal, QC, Canada. Abstract 939.
36.
MirochnickM., KafulafulaG., KreitchmannR.Pharmacokinetics (PK) of tenofovir disoproxil fumarate (TDF) after administration to HIV-1 infected pregnant women and their newborns.16th Conference on Retroviruses and Opportunistic Infections. 8–11 February 2009, Montreal, QC, Canada. Abstract 137.
37.
ChiB.H., SinkalaM., MbeweF.Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial. Lancet2007; 370: 1698–1705.
38.
BestB., StekA., HuC.High-dose lopinavir and standard-dose emtricitabine pharmacokinetics during pregnancy and post-partum.15th Conference on Retroviruses and Opportunistic Infections. 3–6 February 2008, Boston, MA, USA. Abstract 629.
39.
HirtD., UrienS., ReyE.Population pharmacokinetics of emtricitabine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Antimicrob Agents Chemother2009; 53: 1067–1073.
40.
Bennetto-HoodC., BrysonY.J., StekA., KingJ.R., MirochnickM., AcostaE.P.Zidovudine, lamivudine, and nelfinavir concentrations in amniotic fluid and maternal serum. HIV Clin Trials2009; 10: 41–47.
41.
MusokeP., GuayL.A., BagendaD.A Phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS1999; 13: 479–486.
42.
MirochnickM., FentonT., GagnierP.Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis1998; 178: 368–374.
43.
GingelmaierA., KurowskiM., KastnerR.Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery. AIDS2006; 20: 1737–1743.
44.
CapparelliE.V., AweekaF., HittiJ.Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics. HIV Med2008; 9: 214–220.
45.
IvanovicJ., NicastriE., AnceschiM.M.Transplacental transfer of antiretroviral drugs and newborn birth weight in HIV-infected pregnant women. Curr HIV Res2009; 7: 620–625.
46.
IvanovicJ., ViscioneM., NicastriE.TDM of antiretroviral drugs inHIV-infected pregnant women: transplacental diffusion, newborn clinical status and maternal immuno-virological outcome.11th International Workshop on Clinical Pharamcology of HIV Therapy. 7–9 April 2010, Sorrento, Italy. Abstract 14.
47.
ArrivéE., NewellM.L., EkoueviD.K.Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int J Epidemiol2007; 36: 1009–1021.
48.
NightingaleS.L.From the Food and Drug Administration. JAMA1998; 280: 1472.
49.
ChersichM.F., UrbanM.F., VenterF.W.Efavirenz use during pregnancy and for women of child-bearing potential. AIDS Res Ther2006; 3: 11.
50.
LeeC.G., GottesmanM.M., CardarelliC.O.HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry1998; 37: 3594–3601.
51.
SrinivasR.V., MiddlemasD., FlynnP., FridlandA.Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters. Antimicrob Agents Chemother1998; 42: 3157–3162.
52.
MarzoliniC., RudinC., DecosterdL.A.Transplacental passage of protease inhibitors at delivery. AIDS2002; 16: 889–893.
53.
MirochnickM., DorenbaumA., HollandD.Concentrations of protease inhibitors in cord blood after in utero exposure. Pediatr Infect Dis J2002; 21: 835–838.
54.
StekA.M., MirochnickM., CapparelliE.Reduced lopinavir exposure during pregnancy. AIDS2006; 20: 1931–1939.
55.
ChappuyH., TreluyerJ.M., ReyE.Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus. Am J Obstet Gynecol2004; 191: 558–562.
56.
CapparelliE., StekA., BestB.Boosted fosamprenavir pharmacokinetics during pregnancy.17th Conference on Retroviruses and Opportunistic Infections. 16–19 February 2010, San Francisco, CA, USA. Abstract 908.
57.
LecheltM., LyonsF., ClarkeA., MagayaV., IssaR., de RuiterA.Human placental transfer of atazanavir: a case report. AIDS2006; 20: 307.
58.
RipamontiD., CattaneoD., MaggioloF.Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. AIDS2007; 21: 2409–2415.
59.
ConradieF., ZorillaC., JosipovicD.The saftey, efficacy and steady state pharmacokinetics of atazanavir/ritonavir (ATV/r) once daily given in combination with twice daily AZT/3TC during pregnancy: results of study AI424182.5th IAS Conference on HIV Pathogenesis and Treatment. 19–22 July 2009, Cape Town, South Africa. Abstract LBPEB06.
60.
BestB.M., StekA.M., MirochnickM.Lopinavir tablet pharmacokinetics with an increased dose during pregnancy. J Acquir Immune Defic Syndr2010; 54: 381–388.
61.
SoricM., GingelmaierA., KaestnerR.A German cohort of 54 HIV and LPV/r exposed pregnancies-pharmacokinetics, placental transfer and pregnancy outcome.XVII International AIDS Conference. 3–8 August 2008, Mexico City, Mexico. Abstract CDB0204.
62.
RipamontiD., CattaneoD., CortinovisM., MaggioloF., SuterF.Transplacental passage of ritonavir-boosted darunavir in two pregnant women. Int J STD AIDS2009; 20: 215–216.
63.
IvanovicJ., BellagambaR., NicastriE.Use of darunavir/ritonavir once daily in treatment-naive pregnant woman: pharmacokinetics, compartmental exposure, efficacy and safety. AIDS2010; 24: 1083–1084.
64.
PinnettiC., TamburriniE., RagazzoniE., De LucaA., NavarraP.Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1. Antivir Ther2010; 15: 127–129.
65.
BestB., CaparelliE., StekA.Raltegravir pharmacokinetics during pregnancy.50th Interscience Conference on Antimicrobial Agents and Chemotherapy. 12–15 September 2010, Boston, MA, USA. Abstract H-1668a.
66.
McKeownD.A., RosenvingeM., DonaghyS.High neonatal concentrations of raltegravir following transplacental transfer in HIV-1 positive pregnant women. AIDS2010; 24: 2416–2418.
67.
de WildtS.N., KearnsG.L., LeederJ.S., van den AnkerJ.N.Glucuronidation in humans. Pharmacogenetic and developmental aspects. Clin Pharmacokinet1999; 36: 439–452.
WintersM.A., Van RompayK.K., KashubaA.D., ShulmanN.S., HolodniyM.Maternal-fetal pharmacokinetics and dynamics of a single intrapartum dose of maraviroc in rhesus macaques. Antimicrob Agents Chemother2010; 54: 4059–4063.
70.
CeccaldiP.F., FerreiraC., GavardL., GilS., PeytavinG., MandelbrotL.Placental transfer of enfuvirtide in the ex vivo human placenta perfusion model. Am J Obstet Gynecol2008; 198: 433.e1–2.
71.
Brennan-BensonP., PakianathanM., RiceP.Enfurvitide prevents vertical transmission of multidrug-resistant HIV-1 in pregnancy but does not cross the placenta. AIDS2006; 20: 297–299.
72.
GhosnJ., ChaixM.L., PeytavinG.Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men. AIDS2004; 18: 1958–1961.
73.
FurcoA., GosraniB., NicholasS.Successful use of darunavir, etravirine, enfuvirtide and tenofovir/emtricitabine in pregnant woman with multiclass HIV resistance. AIDS2009; 23: 434–435.
74.
SastryB.V.Techniques to study human placental transport. Adv Drug Deliv Rev1999; 38: 17–39.
75.
BourgetP., RoulotC., FernandezH.Models for placental transfer studies of drugs. Clin Pharmacokinet1995; 28: 161–180.
76.
GarlandM.Pharmacology of drug transfer across the placenta. Obstet Gynecol Clin North Am1998; 25: 21–42.
77.
NauH., LuckW., KuhnzW.Decreased serum protein binding of diazepam and its major metabolite in the neonate during the first postnatal week relate to increased free fatty acid levels. Br J Clin Pharmacol1984; 17: 92–98.
78.
KrauerB., DayerP., AnnerR.Changes in serum albumin and alpha 1-acid glycoprotein concentrations during pregnancy: an analysis of fetal-maternal pairs. Br J Obstet Gynaecol1984; 91: 875–881.
79.
WoodM., WoodA.J.Changes in plasma drug binding and alpha 1-acid glycoprotein in mother and newborn infant. Clin Pharmacol Ther1981; 29: 522–526.
80.
HamarC., LevyG.Serum protein binding of drugs and bilirubin in newborn infants and their mothers. Clin Pharmacol Ther1980; 28: 58–63.
81.
SudhakaranS., RaynerC.R., LiJ., KongD.C., GudeN.M., NationR.L.Differential protein binding of indinavir and saquinavir in matched maternal and umbilical cord plasma. Br J Clin Pharmacol2007; 63: 315–321.
82.
GavardL., GilS., PeytavinG.Placental transfer of lopinavir/ritonavir in the ex vivo human cotyledon perfusion model. Am J Obstet Gynecol2006; 195: 296–301.
83.
NanovskayaT., DeshmukhS., BrooksM., AhmedM.S.Transplacental transfer and metabolism of buprenorphine. J Pharmacol Exp Ther2002; 300: 26–33.
84.
KimA.E., DintamanJ.M., WaddellD.S., SilvermanJ.A.Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J Pharmacol Exp Ther1998; 286: 1439–1445.
85.
HuismanM.T., SmitJ.W., SchinkelA.H.Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS2000; 14: 237–242.
86.
HuangL., WringS.A., WoolleyJ.L., BrouwerK.R., Serabjit-SinghC., PolliJ.W.Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Drug Metab Dispos2001; 29: 754–760.
87.
StorchC.H., TheileD., LindenmaierH., HaefeliW.E., WeissJ.Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem Pharmacol2007; 73: 1573–1581.
88.
GerkP.M., VoreM.Regulation of expression of the multidrug resistance-associated protein 2 (MRP2) and its role in drug disposition. J Pharmacol Exp Ther2002; 302: 407–415.
89.
AllikmetsR., SchrimlL.M., HutchinsonA., Romano-SpicaV., DeanM.A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res1998; 58: 5337–5339.
90.
Cordon-CardoC., O'BrienJ.P., BocciaJ., CasalsD., BertinoJ.R., MelamedM.R.Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem1990; 38: 1277–1287.
91.
SugawaraI., KataokaI., MorishitaY.Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Res1988; 48: 1926–1929.
92.
SmitJ.W., HuismanM.T., van TellingenO., WiltshireH.R., SchinkelA.H.Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J Clin Invest1999; 104: 1441–1447.
93.
SudhakaranS., RaynerC.R., LiJ., KongD.C., GudeN.M., NationR.L.Inhibition of placental P-glycoprotein: impact on indinavir transfer to the foetus. Br J Clin Pharmacol2008; 65: 667–673.
94.
MölsäM., HeikkinenT., HakkolaJ.Functional role of P-glycoprotein in the human blood-placental barrier. Clin Pharmacol Ther2005; 78: 123–131.
95.
HuismanM.T., SmitJ.W., WiltshireH.R., HoetelmansR.M., BeijnenJ.H., SchinkelA.H.P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol Pharmacol2001; 59: 806–813.
96.
St-PierreM.V., SerranoM.A., MaciasR.I.Expression of members of the multidrug resistance protein family in human term placenta. Am J Physiol Regul Integr Comp Physiol2000; 279: R1495–R1503.
97.
FlensM.J., ZamanG.J., van der ValkP.Tissue distribution of the multidrug resistance protein. Am J Pathol1996; 148: 1237–1247.
98.
JannehO., AnwarT., JungbauerC.P-glycoprotein, multidrug resistance-associated proteins and human organic anion transporting polypeptide influence the intracellular accumulation of atazanavir. Antivir Ther2009; 14: 965–974.
99.
HuismanM.T., SmitJ.W., CrommentuynK.M.Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS2002; 16: 2295–2301.
100.
MirochnickM.Antiretroviral pharmacology in pregnant women and their newborns. Ann N Y Acad Sci2000; 918: 287–297.
101.
HakkolaJ., RaunioH., PurkunenR.Detection of cytochrome P450 gene expression in human placenta in first trimester of pregnancy. Biochem Pharmacol1996; 52: 379–383.
102.
KoskelaS., HakkolaJ., HukkanenJ.Expression of CYP2A genes in human liver and extrahepatic tissues. Biochem Pharmacol1999; 57: 1407–1413.
103.
PasanenM., Helin-MartikainenH.L., PelkonenO., KirkinenP.Intrahepatic cholestasis of pregnancy impairs the activities of human placental xenobiotic and steroid metabolizing enzymes in vitro. Placenta1997; 18: 37–41.
104.
McRobieD.J., GloverD.D., TracyT.S.Effects of gestational and overt diabetes on human placental cytochromes P450 and glutathione S-transferase. Drug Metab Dispos1998; 26: 367–371.
105.
AherneW., DunnillM.S.Morphometry of the human placenta. Br Med Bull1966; 22: 5–8.
106.
KaufmannP., ScheffenI.Placental development. Philadelphia: Saunders, WB1992; pp. 47–56.
107.
CotterA.M., GarciaA.G., DuthelyM.L., LukeB., O'SullivanM.J.Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth?J Infect Dis2006; 193: 1195–1201.
108.
TownsendC.L., Cortina-BorjaM., PeckhamC.S., TookeyP.A.Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. AIDS2007; 21: 1019–1026.
109.
European Collaborative Study. Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. J Acquir Immune Defic Syndr2003; 32: 380–387.
110.
TuomalaR.E., ShapiroD.E., MofensonL.M.Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med2002; 346: 1863–1870.
111.
BriandN., MandelbrotL., Le ChenadecJ.No relation between in-utero exposure to HAART and intrauterine growth retardation. AIDS2009; 23: 1235–1243.
112.
KourtisA.P., SchmidC.H., JamiesonD.J., LauJ.Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis. AIDS2007; 21: 607–615.
113.
EkoueviD.K., CoffieP.A., BecquetR.Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Cote d'Ivoire. AIDS2008; 22: 1815–1820.
114.
FloridiaM., RavizzaM., BucceriA.Factors influencing gestational age-adjusted birthweight in a national series of 600 newborns from mothers with HIV. HIV Clin Trials2008; 9: 287–297.
115.
The Perinatal Safety Review Working Group.Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts. J Acquir Immune Defic Syndr2000; 25: 261–268.
116.
BlancheS., TardieuM., RustinP.Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet1999; 354: 1084–1089.
117.
BarretB., TardieuM., RustinP.Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort. AIDS2003; 17: 1769–1785.
